MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AdvaMed Speaks Out Against Anti-Preemption Bill

The Medical Device Safety Act of 2008 would overturn the "federal preemption" clause in the 1976 Medical Device Amendments that allowed Medtronic to win a Supreme Court case earlier this year. AdvaMed late yesterday issued a statement against it.

"A patchwork approach to medical device approvals where state courts effectively review and regulate medical devices would likely result in a dizzying array of conflicting labeling and indications for use and ultimately may result in life-saving, life-enhancing technologies simply not being available for patients," said AdvaMed President Stephen J. Ubl. The case, Riegel v. Medtronic, concerned a patient who was injured by a Medtronic catheter in 1996. The 1976 law stated that makers of PMA products cannot be sued in state courts if the products did not violate federal laws and regulations. It established FDA as the sole arbiter of safety and effectiveness of PMA products. This "preemption" of lawsuits in state courts does not apply to 510(k) products, nor to PMA products that are found to be adulterated or misbranded. (The Medtronic catheter was neither. Instead, it was misused by the patient's doctor.) The consequences of allowing such cases to proceed in state courts could allow states to set their own standards for safety and effectiveness of PMA products, which would be chaotic, Ubl said. âEURoeThe Supreme CourtâEUR(TM)s 8-1 decision in Riegel v. Medtronic re-affirmed what most Federal courts have regarded as settled law since 1976 -- that the FDA, not differing state regulations and multiple jury verdicts, should determine the safety and effectiveness of medical technology," he said. "This bill will not improve patient safety but will result in needless delays in patient access to essential medical technologies, more lawsuits and ultimately higher health care costs.âEUR

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.